The liver serves as a crucial organ for metabolic regulation, detoxification, and synthesis of essential proteins. However, its ability to regenerate is hindered when faced with chronic injury, ultimately leading to fibrosis. Fibrogenesis is driven by a complex interaction between liver cells, immune responses, and cytokine signaling. This intricate network creates an environment conducive to the progression of fibrosis. Here, apigenin’s role becomes pivotal. It has been shown to exert anti-inflammatory and antioxidant properties, making it a potentially effective agent in reversing liver injury.

Research indicates that apigenin directly impacts hepatic stellate cells (HSCs), the primary mediators of liver fibrosis. Under pathological conditions, these cells undergo activation and proliferate, contributing to collagen deposition. Apigenin has been found to inhibit HSC activation and induce apoptosis in these cells. By targeting specific signaling pathways, the flavonoid disrupts fibrogenic processes at multiple levels. This effect not only halts the advancement of fibrosis but may also favor the resolution of established scars in the liver.

The study elucidates the mechanistic pathways through which apigenin operates. It is known to modulate key signaling cascades, particularly transforming growth factor-beta (TGF-β), a fundamental player in fibrosis development. TGF-β stimulates HSC activation and extracellular matrix production, promoting fibrotic progression. Apigenin, through its action on TGF-β signaling, presents a feasible approach to mitigating these pathological changes. This modulation is particularly significant as it not only addresses the symptoms but also targets the underlying mechanisms of fibrosis.

Furthermore, the antioxidant properties of apigenin play a critical role in its protective effects on the liver. Oxidative stress is a well-established contributor to liver damage and fibrogenesis. By scavenging free radicals and reducing oxidative stress, apigenin aids in preserving liver function and attenuating the inflammatory response. This dual action of combating oxidative damage while directly inhibiting fibrogenic pathways enhances its therapeutic potential, establishing apigenin as a holistic agent against liver fibrosis.

Considering the implications of these findings, the potential for apigenin in clinical applications grows. Its low toxicity profile and natural origins align well with the current demand for safer, more effective treatment options for chronic liver diseases. Beyond antifibrotic effects, apigenin may also contribute to overall liver health by enhancing metabolic pathways and protecting against further oxidative stress. This could represent a significant advancement in liver health management, particularly for individuals at risk of developing fibrosis due to chronic liver disease.

Additionally, apigenin’s versatility extends to its role in modulating immune responses. Liver fibrosis often results in dysregulated immune activation, which can exacerbate tissue injury. By influencing cytokine release and immune cell activity, apigenin may restore a more balanced immune environment in the liver. This immunomodulatory effect could prove invaluable in the context of liver disease, where inflammation and fibrosis often go hand in hand.

The broad spectrum of benefits associated with apigenin invites further investigation into its mechanisms and efficacy. Existing studies pave the way for clinical trials to evaluate its therapeutic potential in human populations. Establishing optimal dosages, treatment durations, and specific patient populations will be critical in harnessing the full power of apigenin. As research progresses, particularly in translational studies, the hope is to identify effective treatment protocols that can be integrated into existing therapeutic frameworks for liver disease.

In a landscape where liver disease remains a pressing concern globally, the emergence of compounds like apigenin opens new avenues for innovative treatment strategies. Its natural origin and multi-targeted action set it apart from conventional pharmaceuticals that may come with significant side effects. The future of liver fibrosis treatment could very well lie in the integration of natural compounds, heralding a shift towards more holistic healthcare practices that prioritize patient safety and efficacy.

As the scientific community continues to uncover the layers of complexity surrounding liver health, the role of dietary flavonoids like apigenin underscores the potential of nutritional interventions in mitigating disease. The alignment of research findings with public health initiatives promotes awareness of diet’s role in disease prevention and management, fostering an informed approach to liver health that emphasizes the power of food as medicine.

In conclusion, the insights derived from the latest research on apigenin emerging as a multifunctional flavone underscore a significant shift in how we perceive and approach liver fibrosis. The interplay between cellular signaling, immune response, and oxidative stress highlights a comprehensive mechanism warranted further exploration. As we stand on the cusp of potential advancements in liver disease treatment, compounds like apigenin beckon a hopeful future, one where integrative and natural therapies may play a key role in promoting liver health and reversing the tide of fibrosis.

Subject of Research: Liver fibrosis and the effect of apigenin on fibrogenic signaling pathways.

Article Title: Apigenin as a multifunctional flavone against liver fibrosis: mechanistic insights into its modulation of key fibrogenic signalling pathways.

Article References: Singh, L., Kalia, R., Sharma, S. et al. Apigenin as a multifunctional flavone against liver fibrosis: mechanistic insights into its modulation of key fibrogenic signalling pathways. 3 Biotech 16, 32 (2026). https://doi.org/10.1007/s13205-025-04641-7

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s13205-025-04641-7

Keywords: Liver fibrosis, Apigenin, Fibrogenesis, Hepatic stellate cells, TGF-β, Antioxidant properties, Immune modulation, Natural compounds.

Central to pulmonary fibrosis is the remarkable upregulation of the arginine–proline metabolic axis, which fuels excessive extracellular matrix (ECM) deposition. Proline and its hydroxylated form constitute approximately one-third of the collagen amino acid composition, underscoring their critical involvement in fibrotic progression. The metabolic conversion of arginine to ornithine, followed by its transformation into proline via ornithine aminotransferase (OAT) and pyrroline-5-carboxylate reductase 1 (PYCR1), is markedly enhanced in fibrotic lungs. This enzymatic cascade not only facilitates collagen synthesis but also intertwines with canonical fibrotic signaling pathways, notably transforming growth factor-beta 1 (TGF-β1).

Intriguingly, OAT serves as a pivotal node linking metabolic flux to fibrogenic signaling. Beyond its enzymatic role, OAT potentiates TGF-β1 activation, amplifying both Smad-dependent and alternative signaling cascades that sustain fibroblast activation and matrix production. This enzyme further induces proline dehydrogenase (PRODH), catalyzing mitochondrial reactive oxygen species (ROS) generation, which reinforces fibrotic signaling. PYCR1, often complexed with the cytoskeletal adaptor kindlin-2, facilitates mitochondrial proline biosynthesis and stabilizes collagen assembly. Both genetic disruption of kindlin-2 and the anti-fibrotic agent pirfenidone mitigate PYCR1 activity, proline synthesis, and fibrosis severity, highlighting the therapeutic potential of targeting this axis.

Arginine transport into cells is an additional regulatory checkpoint in fibrogenesis. The cationic amino acid transporter-2 (CAT-2) mediates the uptake of arginine, which is essential for arginase activity and subsequent collagen production, specifically within macrophages. Arginase-1 predominantly expresses in macrophages, while arginase-2 localizes more broadly, including myofibroblasts. Notably, arginase-2 colocalizes with heat shock protein 47 (Hsp47), a chaperone integral to collagen maturation, further cementing the relationship between arginine metabolism and ECM synthesis. Pharmacological inhibition of arginase suppresses TGF-β1-induced collagen deposition in both human and murine fibrotic models, emphasizing its candidacy as a therapeutic target.

Paradoxically, arginine also gives rise to polyamines, such as spermidine and creatine, which exert anti-fibrotic effects through mechanisms involving oxidative stress mitigation and autophagy induction. Levels of these polyamines are conspicuously diminished in fibrotic lungs, and their supplementation attenuates disease severity by counteracting cellular stress. This duality in arginine metabolism—fueling fibrosis via proline production while simultaneously generating anti-fibrotic metabolites—reflects the complex metabolic reprogramming within fibrotic tissues.

Complementing the arginine–proline axis, the arginine–nitric oxide synthase (NOS) pathway plays a nuanced and context-dependent role in pulmonary fibrosis. Nitric oxide (NO), produced by NOS enzymes using L-arginine as a substrate, displays dichotomous effects on fibrosis. Inducible NOS (iNOS or NOS2), often upregulated in idiopathic pulmonary fibrosis (IPF), exacerbates inflammation and fibrosis through activation of NF-κB and the NLRP3 inflammasome. Conversely, endothelial NOS (eNOS)-derived NO appears protective by preserving vascular homeostasis and limiting fibrotic injury. This dichotomy suggests that cell-type specific NOS activity dictates divergent outcomes in fibrosis pathogenesis.

A key regulator of NOS function is the enzyme dimethylarginine dimethylaminohydrolase (DDAH), which degrades the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA). Upregulated DDAH in IPF lowers ADMA levels, thereby potentiating NOS2 activity and NO production, which contributes to fibrotic signaling. Importantly, pharmacological inhibition of DDAH reduces TGF-β/Smad-dependent collagen synthesis and impairs alveolar epithelial cell proliferation, indicating its role as a promising therapeutic target.

Expanding beyond arginine metabolism, glutamine emerges as a critical amino acid modulating pulmonary fibrosis. Glutaminase 1 (GLS1) catalyzes the conversion of glutamine to glutamate, a fundamental step upregulated by TGF-β1 in fibrotic fibroblasts. Glutamate fuels the biosynthesis of proline and alanine, vital substrates for collagen production, and contributes to the generation of α-ketoglutarate (α-KG), an activator of the mechanistic target of rapamycin complex 1 (mTORC1). mTORC1 signaling promotes proline hydroxylation and collagen stabilization, thereby augmenting ECM accumulation.

The regulatory network governing GLS1 expression is multifaceted, involving SMAD-dependent and PI3K/mTORC2/PDGFR pathways, and is modulated by epigenetic factors such as Sirtuin-7 and FOXO4. Loss of caveolin-1 (CAV1), a negative regulator of YAP1 activity in fibroblasts, further enhances GLS1 expression in fibrotic lungs. Pharmacological inhibition of GLS1 curtails fibroblast proliferation and collagen synthesis, yet compensatory metabolic pathways exist, underscoring the need for comprehensive strategies targeting glutamine metabolism.

Glycine, constituting one-third of collagen amino acids, represents another indispensable metabolite driving fibrotic ECM biosynthesis. The serine–glycine biosynthesis pathway is profoundly enhanced in pulmonary fibrosis, orchestrated by TGF-β-mediated upregulation of enzymes including PHGDH, PSAT1, PSPH, and SHMT1/2. This metabolic remodeling is supported by increased glycolytic flux, generating 3-phosphoglycerate as a precursor for glycine synthesis. The transcription factor ATF4, activated downstream of TGF-β and mTORC1 signaling, governs serine–glycine biosynthetic enzymes and amino acid transporters, establishing a metabolic milieu favoring ECM deposition.

Tryptophan metabolism exerts a paradoxical influence on pulmonary fibrosis, with metabolites exhibiting both pro- and anti-fibrotic activities. Elevated tryptophan and its derivative serotonin foster fibrotic signaling via enhancement of TGF-β1 pathways and promotion of inflammation. Conversely, indole-3-acetic acid (IAA), produced by gut microbiota, and the derivative 5-methoxytryptophan (5-MTP) exhibit anti-fibrotic properties by inhibiting PI3K/AKT/mTOR signaling and fibroblast activation. The kynurenine pathway (KP) further complicates this landscape: kynurenine activates the aryl hydrocarbon receptor (AhR), suppressing fibroblast activation and migration, yet under certain conditions can exacerbate IL-17A-dependent inflammation, highlighting the nuanced immunometabolic interplay in fibrosis.

Oxidative stress management in fibrotic lungs is intricately linked to the glutathione (GSH) system, synthesized from glutamate, cysteine, and glycine. In IPF, GSH levels are notably depleted, attributed to suppression of glutamate–cysteine ligase (GCL) and GSH synthetase activities via TGF-β1 signaling and post-translational modifications. Reduced GSH exacerbates oxidative damage, promotes fibroblast proliferation, and augments ECM deposition. Conversely, increased extracellular cysteine/cystine redox potential potentiates fibrotic signaling, demonstrating the delicate balance between antioxidant defenses and redox-mediated fibroblast activation. Genetic models highlight the paradox where impairment of GSH degradation enzymes attenuates fibrosis by limiting cysteine availability and associated matrix remodeling.

Methionine metabolism has also been implicated in IPF pathogenesis. Elevated methionine transport into the lungs, alongside upregulated methionine aminopeptidase 2 (MetAP2), promotes fibroblast proliferation and collagen deposition. Pharmacological blockade of MetAP2 hinders these fibrogenic processes, positioning this enzyme as a novel therapeutic target. Intriguingly, deficiency of D-amino acid oxidase (DAO), responsible for degrading D-amino acids, predisposes to aggravated fibrosis, possibly through disrupted metabolic and immune signaling. DAO also modulates alveolar epithelial cell senescence, influencing epithelial repair and fibrosis.

The complexity of amino acid metabolism in pulmonary fibrosis underscores a finely tuned network where metabolic fluxes converge with canonical signaling pathways and epigenetic modifications. The intertwined roles of arginine, glutamine, glycine, tryptophan, cysteine, and methionine reflect a systems-level reprogramming that sustains fibroblast activation, ECM overproduction, and oxidative stress. Therapeutic strategies aimed at modulating key metabolic nodes—such as arginase activity, GLS1, PHGDH, DDAH, and PRMTs—hold significant promise for transforming IPF management. Emerging data also advocate for interventions targeting amino acid transporters and post-translational modifying enzymes that regulate protein function and gene expression in fibrosis.

Future research must dissect the cell type-specific contributions and temporal dynamics of these metabolic pathways to balance efficacy with preservation of essential immune and vascular functions. Integrating metabolic profiling with genetic and pharmacologic tools will further unravel the metabolic vulnerabilities exploitable in pulmonary fibrosis. As our understanding advances, metabolically targeted therapies are poised to complement or surpass existing anti-fibrotic agents, potentially altering the bleak prognosis of this formidable disease.

Subject of Research: Metabolic dysregulation and amino acid metabolism in pulmonary fibrosis pathogenesis and therapy.

Article Title: Metabolic dysregulation in pulmonary fibrosis: insights into amino acid contributions and therapeutic potential.

Article References:
Zheng, H., Zhang, L., Wang, C. et al. Metabolic dysregulation in pulmonary fibrosis: insights into amino acid contributions and therapeutic potential. Cell Death Discov. 11, 411 (2025). https://doi.org/10.1038/s41420-025-02715-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02715-2